Business Context and Reporting Period
Company: NewHold Investment Corp. III (SPAC)
Filing Date: May 27, 2026
Event: The SPAC entered into a Business Combination Agreement on May 26, 2026, with NewCleo Ltd., a private company focused on lead-cooled fast reactor technology and mixed-oxide fuel capabilities. The transaction involves a series of mergers where the SPAC will become a wholly-owned subsidiary of the combined entity.
Key Financial Metrics
This Form 8-K is a current report regarding a material event and does not contain audited financial statements, revenue, profit, cash flow, or margin data for the reporting period.
- Trading Symbols: NHICU (Units), NHIC (Class A Ordinary Shares), NHICW (Warrants).
- Warrant Exercise Price: $11.50 per share.
- Liquidity/Debt: Specific debt levels and liquidity positions are not disclosed in this filing. The filing notes that the combined company will likely require substantial additional capital.
Material Changes
The primary material change is the execution of the Business Combination Agreement. This represents a fundamental shift from a standalone SPAC to a proposed merger with an operating advanced nuclear energy company. No prior comparable period financial data is presented in this document to assess year-over-year changes.
Guidance, Outlook, and Risks
Outlook and Management Commentary:
- The combined company intends to develop, license, construct, and commercialize NewCleo's advanced nuclear technologies.
- Management anticipates the need for substantial additional capital to execute its business strategy.
- A Registration Statement on Form F-4 (Proxy Statement/Prospectus) will be filed to solicit shareholder approval.
Risks and Contingencies:
- Transaction Completion: Risks include failure to obtain shareholder approval, inability to secure private placement financing, or failure to meet closing conditions.
- Redemptions: High levels of redemption by public shareholders could reduce cash available to the combined company and impact liquidity.
- Operational Risks: NewCleo is in an early stage of development with limited operating history. Risks include technical performance, regulatory approvals (US, UK, EU), supply chain challenges, and cost overruns.
- Market Risks: Changes in nuclear energy regulations, geopolitical developments, and competition.
Investor Verification Checklist
- Verify the terms of the Business Combination Agreement filed as Exhibit 2.1.
- Review the upcoming Proxy Statement/Prospectus (Form F-4) for detailed financial projections and valuation metrics.
- Assess the status of private placement financing and the potential impact of shareholder redemptions on the combined company's cash position.
- Confirm the regulatory approval status for NewCleo's lead-cooled fast reactor technology in target jurisdictions.
- Monitor the filing of the definitive proxy statement for voting instructions and record dates.